NDA Resubmitted for Dry Eye Treatment Reproxalap
Biotechnology company Aldeyra Therapeutics announced today the resubmission of a new drug application (NDA) to the FDA for the potential topical dry eye and allergic conjunctivitis treatment reproxalap, according to a news release. The resubmission …